Sellar tuberculoma: a rare presentation in a 30-year-old Ethiopian woman: case report

Background: Tuberculosis rarely involves the hypothalamo-pitutary axis. Only 1% of CNS Tuberculoma involves sellar and suprasellar structures. It mainly presents with symptoms of chiasmal compression, hypopituitarism and diabetes insipidus due to destruction of pituitary itself. Definitive diagnosis is made by tissue analysis collected by trans-sphenoidal biopsy.Case presentation: We report a 30-year-old female patient from Addis Ababa, who presented with a global headache, blurring of vision, excessive polyuria, constitutional symptoms of tuberculosis and multiple axillary lymph node enlargement. Biopsy from the axillary lymph node showed caseous granulomatous lesions and brain MRI showed mild thickening of the pituitary stalk and mildly enlarged posterior piturary lobe with hypo-sellar extension and mild communicating hydrocephalus.Conclusion: Considering the available evidence a diagnosis of systemic tuberculosis involving pituitary, lung and lymph node was made and a patient was started on anti-tuberculosis medication together with dexamethasone and carbamazepine. Following treatment initiation patient showed significant clinical improvement. After nine months of anti-tuberculosis treatment all brain MRI findings were resolved and patient become symptom free and discharged from care after one year completion of anti-tuberculosis medication.Keywords: Tuberculoma, Polyuria, Pituitary gland, Diabetes Insipidu

Medical Admissions and Outcomes at Saint Paul’s Hospital, Addis Ababa, Ethiopia: a retrospective study

Background: Globally, trends of medical admission have been changing. This study was carried out to assess the current trend of medical admissions and outcomes in Ethiopia.Methods: Retrospective review of 840 records of patients admitted to medical ward of Saint Paul hospital during April 1, 2012-March 31, 2013 was done. Ethical approval was obtained from the IRB of the hospital. Data on demographic profiles, reasons for admission, final diagnosis, length of hospital stay and treatment outcomes were recorded by physicians on structured format developed for this purpose. The data were entered & analysed using SPSS software version 20.Results: Most of the patients were from Addis Ababa. The mean age of patients was 40.9±17.7 years, 470 (56%) of the patients were females and 71% were married. Non-communicable diseases (NCDs) contributed to 51.1% of admissions. Communicable diseases were dominant diagnosis for those groups in 35-44 years of age while noncommunicable diseases were dominant diagnosis for those 45-54 years of age and above. The three most common reasons for immediate admission to the hospital were pneumonia 188 (22.4%), tuberculosis 177 (21.1%) and heart failure 134 (16.0%). And the major diagnoses for underlying illnesses during admissions were found to be AIDS 177 (21.1%), hypertension 102 (12.1%), diabetes mellitus 102 (12.1%), atherosclerotic cardio vascular disorders 86 (10.2%), gastrointestinal disorders 56 (6.7%), valvular heart diseases 51 (6.1%), and renal failure 46 (5.5%). Mean duration of stay in medical wards was 12.3 (+/-10) days and it is comparable for communicable diseases and non-communicable diseases. Two third of the medical admissions (66.4%) were discharged improved while mortality was close to one fourth (24.2%). Communicable diseases contributed to two thirds of the mortality (15.6%).Conclusion: Non-communicable diseases were the major cause of admission to the hospital while communicable diseases contributed to two thirds of the overall mortality predominantly among the younger patients. Health professionals, policy-makers and health planners should recognize the higher morbidity and hospital burden from non-communicable diseases and the higher mortality from communicable diseases. Key words: Medical admission, communicable and non-communicable, morbidity, mortality, Ethiopi

Prevalence of human papillomavirus and Helicobacter pylori in esophageal and gastroesophageal junction cancer biopsies from a case-control study in Ethiopia

peer reviewe

Global prevalence and genotype distribution of hepatitis C virus infection in 2015 : A modelling study

Publisher Copyright: © 2017 Elsevier LtdBackground The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the recent launch of direct acting antiviral therapies. Reliable disease burden estimates are required for national strategies. This analysis estimates the global prevalence of viraemic HCV at the end of 2015, an update of—and expansion on—the 2014 analysis, which reported 80 million (95% CI 64–103) viraemic infections in 2013. Methods We developed country-level disease burden models following a systematic review of HCV prevalence (number of studies, n=6754) and genotype (n=11 342) studies published after 2013. A Delphi process was used to gain country expert consensus and validate inputs. Published estimates alone were used for countries where expert panel meetings could not be scheduled. Global prevalence was estimated using regional averages for countries without data. Findings Models were built for 100 countries, 59 of which were approved by country experts, with the remaining 41 estimated using published data alone. The remaining countries had insufficient data to create a model. The global prevalence of viraemic HCV is estimated to be 1·0% (95% uncertainty interval 0·8–1·1) in 2015, corresponding to 71·1 million (62·5–79·4) viraemic infections. Genotypes 1 and 3 were the most common cause of infections (44% and 25%, respectively). Interpretation The global estimate of viraemic infections is lower than previous estimates, largely due to more recent (lower) prevalence estimates in Africa. Additionally, increased mortality due to liver-related causes and an ageing population may have contributed to a reduction in infections. Funding John C Martin Foundation.publishersversionPeer reviewe

Chronic viral hepatitis: policy, regulation, and strategies for its control and elimination in Ethiopia

Abstract Background Hepatitis B and C are silent killers not yet recognized as major public health challenges in many developing countries with huge disease burden. In Ethiopia, Hepatitis B is endemic with an average prevalence of 10.8 %, and the prevalence of Hepatitis C is 2 %. The prevalence of both infections, however, is likely to be underreported due to the lack of diagnostic facilities and appropriate surveillance systems. Ethiopia is also among the many Sub-Sahara African countries lacking a coordinated and systematic national response to chronic viral hepatitis. The objective of this study is to examine the current level of response to viral Hepatitis B & C in Ethiopia with the aim to bring identified gaps to the attention of relevant stakeholders and policy makers. Methods This cross-sectional qualitative study was based on semi-structured in-depth interviews with 21 key informants from health facilities, health offices, pharmaceutical companies, regulatory bodies, professional association and blood bank units. Participants were selected purposively based on their role in the national hepatitis response. The investigators also reviewed available policy and strategy documents, standards of practice and surveys, and paid visits to pharmaceutical premises to check the availability of antiviral drugs. Thematic analysis was employed to make sense of the data. During the data analysis process, all the authors critically read the materials, and data was triangulated by source, interpreter view and thematic perspective to ensure accurate representation and comprehensiveness, and validation of the interviewees’ responses. Once each investigator reviewed the data independently, the team reached a common understanding of the scope and contexts of the information attained. Data were subsequently reduced to key concepts, and case stories were taken with successive revisions. The key concepts were later coded into most basic meaningful categories. The World Health Organization (WHO) global hepatitis response framework was used to organize the analysis. Results Ethiopia is in the process of preparing strategic plan and guidelines for viral hepatitis. However, the country still lacks the required partnerships, and resource mobilization as a national health response is limited. Community awareness on the disease transmission and its sequel is poor. Viral hepatitis screening services are not widely available except for the occasional mandatory medical checkups for work or travel purposes. Healthcare providers often take no further action after diagnosing patients with viral hepatitis due to lack of treatment guidelines and strategic frameworks for screening, diagnosis, and treatment. Besides, drugs that are effective in the treatment of viral hepatitis are not available, mainly due to regulatory challenges. Conclusions Viral hepatitis and its disease burden are getting little attention in Ethiopia and many low-income countries. The levels of technical guidance and financial support from the international community are low. To date, the response to the infections in Ethiopia is patchy. Thus, the country needs to formulate policy and strategies in the areas of disease surveillance, risk group identification and screening, use of the birth dose of hepatitis B vaccine, and care and treatment. Improving availability of data on viral hepatitis, access to low-cost generic drugs and developing and dissemination of treatment guidelines are also critical. Leveraging the successful Health Extension Program for a hepatitis response, and exploring ways to learn from and integrate into the HIV/AIDS program should also be considered

Drug-induced esophageal injuries with an atypical presentation mimicking acute coronary syndrome

Abstract Background Pill-induced esophageal injury may cause severe complications if not diagnosed in a timely fashion. The condition is under-recognized and under-reported, and some patients present with atypical clinical or endoscopic features mimicking other common conditions. If the diagnosis is missed the patient will continue to take the offending drug, potentially worsening the illness. We present a case in which acute coronary syndrome was the initial working diagnosis leading to a delay in diagnosis of doxycycline-induced esophageal injury. The patient developed multiple esophageal ulcers and hemorrhage. Case presentation A 50-year-old male driver with a history of hypertension and dyslipidemia was brought to the emergency department with complaints of severe retrosternal chest pain, vomiting, diaphoresis and syncope. On initial evaluation, acute coronary syndrome was considered due to the clinical presentation and history of cardiovascular risk factors. Electrocardiogram and serum troponins were normal. On the second day of his admission, the patient developed odynophagia and bloody vomitus. Esophagogastroduodenoscopy revealed extensive esophageal ulcerations with hemorrhage. The patient was taking Doxycycline capsules for an acute febrile illness. Doxycycline is the oral medication most commonly reported to cause esophageal injury. Doxycycline was discontinued, and the patient was treated with intravenous omeprazole and oral antacid suspension. The patient improved, was discharged after 6 days of hospitalization, and reported resolution of all symptoms at an outpatient follow-up visit 3 weeks later. Conclusion Medication-induced esophageal injury can present with atypical symptoms mimicking acute coronary syndrome. This condition should be included in the initial differential diagnosis of patients presenting with acute chest pain, especially those taking oral medications known to cause esophageal injury